AM
Andrew J. Muir
Elite in Hepatitis C

Dr. Andrew J. Muir

Duke Specialty Infusion Center
Durham, NC
Elite
 in Hepatitis C
Specialties:Gastroenterology
Experience:30 Years
Age:56
Clinical Trials:Currently Recruiting for 5 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Andrew J. Muir's experience treating your condition:
About Dr. Andrew J. Muir

Andrew Muir is a Gastroenterologist in Durham, North Carolina. Muir has been practicing medicine for over 30 years and is rated as an Elite expert by MediFind in the treatment of Hepatitis C. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Sclerosing Cholangitis, Cholangitis, and Liver Transplant. He is licensed to treat patients in North Carolina. Muir is currently accepting new patients.

His clinical research consists of co-authoring 198 peer reviewed articles and participating in 21 clinical trials in the past 15 years. In particular, he has co-authored 117 articles and participated in 9 clinical trials in the study of Hepatitis C.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Andrew J. Muir it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
30 Duke Medicine Cir, Durham, NC 27710
Other Locations
10207 Cerny St, Raleigh, NC 27617
Background & Education
Graduate Institution
Duke University School Of Medicine, 1993
Specialties
Gastroenterology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Duke Raleigh Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Enrollment Status: Recruiting
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients With Type 1 Diabetes Mellitus
Enrollment Status: Recruiting
Publish Date: November 03, 2022
Intervention Type: Other, Drug
Study Drugs: Pre-ProinsulinTGF-Beta1IL-10IL-2
Study Phase: Phase 1
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Recruiting
Publish Date: March 18, 2022
Intervention Type: Drug
Study Drug: Sulfasalazine
Study Phase: Phase 2
TrialNet Pathway to Prevention of T1D
Enrollment Status: Recruiting
Publish Date: February 21, 2022
The Insulin-Only Bionic Pancreas Pivotal Trial: Testing the iLet in Adults and Children With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 17, 2022
Intervention Type: Other, Combination Product
Study Phase: Not Applicable
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Active, not recruiting
Publish Date: July 21, 2022
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Enrollment Status: Completed
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
Quality of Life in Primary Sclerosing Cholangitis
Enrollment Status: Completed
Publish Date: January 30, 2020
Intervention Type: Other
Study Phase: Not Applicable
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
COPE-HCV: Continuous Interferon Delivery Via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV
Enrollment Status: Completed
Publish Date: October 09, 2019
Intervention Type: Device, Drug
Study Phase: Phase 2
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Enrollment Status: Unknown status
Publish Date: December 13, 2018
Intervention Type: Device
Study Phase: Not Applicable
Hepatitis C Alcohol Reduction Treatment - Randomized Controlled Trial (Hep ART-RCT)
Enrollment Status: Completed
Publish Date: October 18, 2018
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
Enrollment Status: Completed
Publish Date: August 18, 2017
Intervention Type: Drug
Study Phase: Phase 2
Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus
Enrollment Status: Withdrawn
Publish Date: September 03, 2015
Intervention Type: Drug
View 15 Less Clinical Trials -
198 Total Publications
Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
Journal: Diabetes technology & therapeutics
Published: September 29, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
JM
John G. Mchutchison
Dr. John G. Mchutchison
Gastroenterology
Elite
Highly rated in
10
conditions
Gastroenterology

Duke Family Medicine Center

2100 Erwin Rd, 
Durham, NC 
 0.3 mi

John Mchutchison is a Gastroenterologist in Durham, North Carolina. Mchutchison is rated as an Elite expert by MediFind in the treatment of Hepatitis C. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Cirrhosis, Liver Transplant, and Kidney Transplant. He is licensed to treat patients in North Carolina.

JD
Dr. Jama M. Darling
Gastroenterology
Distinguished
Highly rated in
16
conditions
Gastroenterology

UNC Health

UNC Gastrointestinal Procedures

101 Manning Dr, 
Chapel Hill, NC 
 9.4 mi

Jama Darling is a Gastroenterologist in Chapel Hill, North Carolina. Darling has been practicing medicine for over 27 years and is rated as a Distinguished expert by MediFind in the treatment of Hepatitis C. She is also highly rated in 16 other conditions, according to our data. Her top areas of expertise are Hepatitis, Hepatitis C, Banti's Syndrome, Visceromegaly, and Liver Transplant. She is licensed to treat patients in North Carolina. Darling is currently accepting new patients.

JJ
Dr. Janet A. Jezsik
Gastroenterology
Distinguished
Highly rated in
7
conditions
Gastroenterology

2100 Erwin Rd, 
Durham, NC 
 0.3 mi

Janet Jezsik is a Gastroenterologist in Durham, North Carolina. Jezsik has been practicing medicine for over 37 years and is rated as an Advanced expert by MediFind in the treatment of Hepatitis C. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Hepatitis C, Hepatitis, Jaundice, and Congenital Hepatic Fibrosis. She is licensed to treat patients in North Carolina. Jezsik is currently accepting new patients.